Rethinking Cancer: non-sexy, low-cost therapies
Increasingly, Big Pharma is betting on new blockbuster cancer drugs that cost billions to develop and can be sold for thousands of dollars a dose. In 2010, each of the top 10 cancer drugs topped more than $1 billion in sales, according to Campbell Alliance, a health-care consulting firm. A decade earlier, only two of them did. Left behind are low-cost alternatives — therapies like off-label medications, including generics — that have shown some merit but don’t have enough profit potential for drug companies to invest in researching them. Read the free, in-depth, investigation in Think, Magazine, by ProPublica’s Jake